Strategically Mapping Disease Burden to Clinical Trial Site Locations

Introduction: Disease Burden as the Foundation of Feasibility

In clinical research, finding the right patients in the right places is fundamental to trial success. Site selection that does not align with disease epidemiology risks under-recruitment, poor data diversity, and increased trial costs. Mapping disease burden—through prevalence, incidence, and burden indicators like Disability-Adjusted Life Years (DALYs)—allows sponsors to locate patient-rich geographies and design studies that are both operationally feasible and scientifically robust.

This article explores how feasibility teams can leverage global disease burden data to map site locations, improve enrollment, and fulfill regulatory and ethical imperatives around inclusive, patient-centric research.

1. Understanding Disease Burden Metrics

Three primary data types are used to quantify disease burden for trial feasibility:

• Prevalence: Number of existing cases at a specific time (useful for chronic diseases)
• Incidence: Number of new cases over a period (key for infectious disease and screening studies)
• DALYs/QALYs: Measures of total years lost due to illness, disability, or premature death (indicators of health system burden and unmet need)

These indicators form the epidemiological foundation for targeting trial locations.

2. Global vs Local Disease Mapping Tools

Various tools and databases help visualize disease burden by geography:

• Global Burden of Disease (GBD) by IHME: DALY, prevalence, and incidence across 200+ conditions in 195 countries
• Clinical Trials Registry – India (CTRI): Disease and region-specific registry data
• ClinicalTrials.gov: Historical site data by indication
• Ministry of Health disease surveillance reports
• Hospital networks and insurance claims databases (real-world evidence)

Overlaying this data with demographic and logistical information enables feasibility teams to visualize recruitment hotspots.

3. Aligning Burden with Site Placement: A Case Study

Case Example: A sponsor planned a cardiovascular outcomes trial across Southeast Asia. Using IHME data, they identified the top five provinces in Vietnam with the highest DALYs lost to ischemic heart disease. Instead of defaulting to capital city hospitals, they selected public hospitals in those high-burden zones and recruited 1,200 patients 3 months ahead of schedule.

4. Sample Heatmap: Stroke DALY Distribution in Europe

The data shows that some high-burden areas are underrepresented in site placement, leading to missed opportunities for inclusion and early access to innovation.

5. Feasibility Risk of Poor Burden Mapping

When disease burden is not factored into geographic site planning:

• Recruitment targets are missed due to low eligible patient volume
• Screening failure rates spike due to mismatch between inclusion criteria and available cases
• Site productivity varies widely across regions, complicating timelines and resource allocation
• Diversity in real-world population representation is lost

These outcomes affect not only operational success but also regulatory review and payer acceptability.

6. Burden-Based Site Selection Scorecard

Feasibility teams often use a weighted model to score potential regions. A sample framework:

Sites with highest composite burden-adjusted scores are prioritized for feasibility visits.

7. Tailoring Site Strategy by Disease Type

Disease mapping strategy varies based on condition category:

• Rare Diseases: Use patient registries and specialty center concentration maps
• Non-communicable Diseases (NCDs): Use DALYs + chronic disease prevalence databases
• Infectious Diseases: Use outbreak incidence and contact tracing network maps
• Mental Health: Use WHO MHAT reports and health facility census data

Each condition has its own spatial epidemiology—trial design must reflect that.

8. Integrating Disease Burden into Site Feasibility SOPs

To institutionalize burden-based feasibility, sponsors and CROs should:

• Mandate disease burden mapping in all feasibility assessments
• Train feasibility specialists in basic epidemiology
• Subscribe to global disease mapping tools and databases
• Establish centralized dashboards linking burden to investigator performance
• Revisit site networks annually based on updated GBD data

Such structured approaches reduce over-reliance on investigator preference or past experience and promote data-driven trial planning.

9. Regulatory and Ethical Imperatives

Mapping trials to high-burden areas is also an ethical obligation. It ensures:

• Equitable access to investigational therapies
• Population representativeness for post-marketing application
• Resource alignment with public health needs
• Support for regulatory fast-track programs targeting high-unmet-need regions

Agencies like the FDA and EMA expect burden alignment in trial population justification documents.

Conclusion

Mapping disease burden to site location is a core element of modern clinical trial feasibility. With tools like GBD data, DALY indicators, and patient density analytics, sponsors can identify optimal site geographies that balance scientific relevance, patient access, and operational efficiency. By aligning trial activity with the real-world distribution of disease, we not only improve trial performance but also advance health equity and research integrity worldwide.